



RESEARCH

Open Access



# The smoking and vaping model, A user-friendly model for examining the country-specific impact of nicotine VAPING product use: application to Germany

Luz María Sánchez-Romero<sup>1\*</sup> , Alex C. Liber<sup>1</sup>, Yameng Li<sup>1</sup>, Zhe Yuan<sup>1</sup>, Jamie Tam<sup>2</sup>, Nargiz Travis<sup>1</sup>, Jihyoun Jeon<sup>3</sup>, Mona Issabakhsh<sup>1</sup>, Rafael Meza<sup>3,4,5</sup> and David T. Levy<sup>1</sup> 

## Abstract

**Background** Simulation models play an increasingly important role in tobacco control. Models examining the impact of nicotine vaping products (NVPs) and smoking tend to be highly specialized and inaccessible. We present the Smoking and Vaping Model (SAVM), a user-friendly cohort-based simulation model, adaptable to any country, that projects the public health impact of smokers switching to NVPs.

**Methods** SAVM compares two scenarios. The No-NVP scenario projects smoking rates in the absence of NVPs using population projections, deaths rates, life expectancy, and smoking prevalence. The NVP scenario models vaping prevalence and its impact on smoking once NVPs became popular. NVP use impact is estimated as the difference in smoking- and vaping-attributable deaths (SVADs) and life-years lost (LYLs) between the No-NVP and NVP scenarios. We illustrate SAVM's adaptation to the German adult ages 18+ population, the Germany-SAVM by adjusting the model using population, mortality, smoking and NVP use data.

**Results** Assuming that the excess NVP mortality risk is 5% that of smoking, Germany-SAVM projected 4.7 million LYLs and almost 300,000 SVADs averted associated with NVP use from 2012 to 2060. Increasing the excess NVP mortality risk to 40% with other rates constant resulted in averted 2.8 million LYLs and 200,000 SVADs during the same period.

**Conclusions** SAVM enables non-modelers, policymakers, and other stakeholders to analyze the potential population health effects of NVP use and public health interventions.

**Keywords** Tobacco smoking, Vaping, Prevalence, Computer simulation, Population health, Germany

\*Correspondence:

Luz María Sánchez-Romero  
ls1364@georgetown.edu

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Nicotine Vaping Products (NVPs), or e-cigarettes, are changing the tobacco product landscape. Worldwide, 35 million individuals in 2019 were estimated to use NVPs and heated tobacco products, with these numbers increasing [1, 2]. NVPs are increasingly being used by smokers to quit [3–5], but there is concern about their increased use among youth [6].

NVPs deliver fewer toxicants than cigarettes [7–13] and efficiently deliver nicotine [14–18], thereby potentially serving as a “harm reducing” substitute for cigarettes. Exclusive NVP use reduces harm when used by those who would have instead initiated smoking or by former smokers who switched to NVPs and would not have otherwise quit smoking. NVP use increases harm if used by those who would not have otherwise started any combustible tobacco use or by former smokers who would have otherwise quit all combustible tobacco use [19].

Simulation models offer tools to examine potential public health implications of novel tobacco products like NVPs [20, 21]. They can also be used to identify evidence gaps needed to be filled to better understand the role of NVPs, and to develop effective tobacco control strategies [22, 23]. Globally, many countries are considering or have already restricted NVP availability [24] and could apply simulation models to help guide their decision-making [25]. While many models incorporate NVPs [26–34], most tend to be highly specialized, have substantial input data requirements, and are generally not accessible to researchers without modeling expertise.

The Smoking and Vaping Model (SAVM) adopts a public health framework [19] to assess the possible harm- increasing or -reducing of the use of NVPs in the population health. This framework is based on decision theory that considers the potential pathways of NVP and cigarette use by current, former and never cigarette users. It is based on previous work, which sets out a decision-theoretic analysis [19, 35]. SAVM was developed to be readily available and easily adaptable for non-modeling experts, and to facilitate outcome interpretation and transparency for all input parameters and methodologies. Based on a previous NVP replacement model [36], the SAVM offers greater flexibility by incorporating a wide range of cigarette and NVP initiation and cessation rates and switching parameters. It is developed in Microsoft Excel to remove technical barriers to implementation and facilitate adaptation for user-specific purposes.

Originally developed based on the US population [37], we now discuss the application of the SAVM to other countries. As an illustrative example, we present the model's application for the German population: the Germany-SAVM. Germany was chosen as an example

because there is evidence of increasing NVP consumption. This trend could potentially change because of Germany's NVP permissive policies shifting toward stricter policies [38, 39]. Therefore, evidence on the impact of NVP use from SAVM could support NVP or smoking policy planning and surveillance in Germany. Prior tobacco simulation models for Germany have been used to evaluate smoking but not NVPs [40, 41]; the Germany-SAVM can facilitate decision-making in the era of NVP use.

## Methods

The SAVM is a cohort-based discrete-time simulation model that projects the impact of NVPs for specific birth cohorts in a given population. This approach recognizes that NVP use within a particular year depends on NVPs availability, NVP initiation and cessation rates, and the switching from smoking (i.e., cigarette use) to NVP use at specific ages. The SAVM simulates separate cohorts for males and females by individual age. The population evolves with age (i.e., yearly) and transitions between states are age and gender dependent. The model estimates the public health impact of NVP use by simulating and comparing two scenarios: the No-NVP and the NVP scenarios. The *No-NVP scenario* projects cigarette use and associated mortality outcomes in a country before NVP use became popular. Smoking rates evolve through smoking initiation and cessation. The NVP scenario estimates current and future smoking and vaping prevalence trends from the year that NVPs became more widely used. NVP use evolves through NVP initiation and cessation rates, and switching from cigarette to NVP use. The NVP-scenario for the US population has been previously validated against US smoking and vaping prevalence [37]. The outcomes are derived based on the difference in smoking-attributable deaths (SADs) and smoking-and-vaping-attributable deaths (SVADs) and life years lost (LYLs) between the No-NVP and the NVP scenarios. SAVM's pre-loaded input and transition parameters are based on US data. Adapting the model to other countries requires scaling US data to country-specific rates. However, the developer may substitute the pre-loaded US rates for country-specific rates if the information is available.

## Preliminary steps

First, SAVM requires the user to specify the *modeling period* (i.e., a maximum modeling period of 88 years) and *age ranges* (from 0 to 99 years) considered. The Germany-SAVM modeling period is set from 2012 to 2060.

The user then provides country-specific inputs for population projections, overall mortality, and life expectancy by age and gender for all modeling years (Table 1).

**Table 1** Data and parameters required for the smoking and vaping model

| Input parameters   | Description  | Suggested data sources and pre-loaded estimate (Germany-SAVM) <sup>b</sup>  |
|--|--|---|
| Population ( <i>Compulsory user-input</i> )                                      | Population by age, gender, and year  | <sup>b</sup> United Nations. World Population Prospects [42]  |
| Mortality rates ( <i>Compulsory user-input</i> )                                 | Overall mortality rates by age, gender, and year for never, current, and former smokers  | World Health Organization. The Global Health Observatory [112]<br><sup>b</sup> United Nations. World Population Prospects 2019. Mortality Data [43]   |
| Life expectancy ( <i>Compulsory user-input</i> )                                 | Expected life years remaining of never smokers by age, gender, and year  | Global Health Observatory. Life expectancy and healthy life expectancy [113]<br><sup>b</sup> United Nations. World Population Prospects 2019. Life expectancy at Birth [43]   |
| Smoking prevalence ( <i>Compulsory user-input</i> )                              | Current and former smoking prevalence by age and gender for the initial year.  | Global Health Observatory data repository [114]<br><sup>b</sup> German Health Update <sup>a</sup> (Gesundheit in Deutschland aktuell, GEDA 2012–2013 [46])  |
| Smoking initiation rate for the No-NVP scenario <sup>a</sup>                     | The proportion of male/female never smokers in year <i>t</i> at age <i>a</i> who initiate to current smokers in year <i>t</i> + 1 at age <i>a</i> + 1.   | <sup>b</sup> CISNET Lung Group [61, 82, 115, 116], available on the CISNET website [117] ( <i>Built-in data</i> )   |
| Smoking cessation rate for the No-NVP scenario <sup>a</sup>                      | The proportion of male/female current smokers in year <i>t</i> at age <i>a</i> who quit smoking in year <i>t</i> + 1 at age <i>a</i> + 1. We consider net smoking cessation without any relapse. | <sup>b</sup> CISNET Lung Group [61, 82, 115, 116], available on the CISNET website [117]. ( <i>Built-in data</i> )  |
| NVP relative risk multiplier ( <i>Optional-user input</i> )                      | Excess risk of NVP use measured relative to excess smoking risks (mortality rate of current smokers – mortality rate of never smokers)   | NVP excess mortality risks set at 5% <sup>b</sup> recommended ranges between 2% [80] and 50%.   |
| NVP Switching rate   | Rate of switching from smoking cigarettes to exclusive NVP use   | Ranges from 0.6–4.0%, estimated by age group and gender using prospective analysis from PATH data 2013–2017 ( <i>Built-in data</i> )<br><sup>b</sup> 50% of PATH's switching rates  |
| Rate of decline in the NVP switching rate  | Yearly exponential process (annual change rate) to allow for constant relative change in the individual  | Set at 90%, implying a 10% annual reduction in the NVP switching rate over time<br>Suggested annual rate – 50 to 103% <sup>c</sup>  |
| Smoking initiation multiplier in the NVP Scenario ( <i>Optional-user input</i> ) | Ratio of smoking initiation rate in the NVP Scenario to smoking initiation rate in the No-NVP Scenario   | 75% of the No-NVP smoking initiation rate, based on recent studies [67–69]. ( <i>Built-in data</i> )<br><sup>b</sup> 88% of the No-NVP smoking initiation rate<br>Suggested annual change rate: 50 to + 150% <sup>c</sup>   |
| NVP initiation multiplier in the NVP Scenario ( <i>Optional-user input</i> )     | Ratio of NVP initiation rate in the NVP Scenario to smoking initiation rate in the No-NVP Scenario   | 50% of the No-NVP smoking initiation rate, based on recent studies [118–121]. ( <i>Built-in data</i> )<br><sup>b</sup> 25% of the No-NVP smoking initiation rate<br>Suggested annual change rate: 50 to + 150% <sup>c</sup> |
| Smoking cessation multiplier in the NVP Scenario ( <i>Optional-user input</i> )  | Ratio of smoking cessation rate in the NVP Scenario to smoking cessation rate in the No-NVP Scenario   | <sup>b</sup> 100% of the No-NVP smoking cessation rate ( <i>Built-in data</i> )<br>Suggested annual change rate 50 to + 150% <sup>c</sup>   |
| NVP cessation multiplier in the NVP Scenario ( <i>Optional-user input</i> )      | Ratio of NVP cessation rate in the NVP Scenario to smoking cessation rate in the No-NVP Scenario   | <sup>b</sup> 100% of the No-NVP smoking cessation rate ( <i>Built-in data</i> )<br>Suggested annual change rate: 50 to + 150% <sup>c</sup>  |

<sup>a</sup> Smoking initiation and cessation rates are pre-loaded parameters using US data and do not need to be provided by the user unless country-specific parameters are desired. NVP = nicotine vaping product, No-NVP Scenario = values in the absence of NVP use. NVP Scenario = values with NVP use. PATH = The Population Assessment of Tobacco and Health Study, US.<sup>b</sup> data source used for the Germany-SAVM. <sup>c</sup>Suggested annual change rates higher or lower can result in initiation rates above 100% and cessation rates above 50%. **Bold** Germany specific data sources

German population projection data by single age, total mortality rates by five-year age groups for 2012 to 2060, and 2012 life expectancy were obtained from the United Nations World Population Prospects [42, 43].

Since Germany's overall mortality data was only available by five-year age groups, SAVM transformed that data into single ages by assuming the same death rates for each age within a given age group (SAVM User

Guide, sec 3.2.2) [44]. The 2012 overall life expectancy was transformed into never smokers' life expectancy for each modeling year by multiplying the age and gender-specific life expectancy of US never smokers by the ratio of the 2012 German/US overall life expectancy [45], assuming that each individual age-gender ratio is constant over the modeling period (see SAVM User Guide, sec 3.2.3) [44].

**No-NVP scenario**

The No-NVP scenario projects the prevalence and mortality of never, current, and former smokers over time in the absence of NVPs (Fig. 1). The user enters country-specific never, current, and former smoking prevalence for the first year of the modeling period by age and gender. The smoking prevalence should reflect regular or established cigarette use (i.e., smoked at least 100 cigarettes during their lifetime and currently smokes every day or some days) since regular use is more directly relevant to public health outcomes than occasional use (see Supplementary Table 1 for recommended definitions) [19].


The Germany-SAVM uses smoking prevalence from the “German Health Update” (Gesundheit in Deutschland aktuell [GEDA]) 2012 [46]. Five different German surveys with smoking data were considered (GEDA, the German Health Interview and Examination Survey for Adults [DEGS], Microcensus, The German Study on Tobacco Use [DEBRA], and Eurobarometer) for model building and validation. GEDA was chosen for model building because it is one of the largest nationally representative surveys, and data was available for 2012 before significant NVP use in Germany [47–49].

GEDA defines current smokers as those who smoke any combustibles, including manufactured cigarettes, hand-rolled cigarettes, cigars, or pipes (daily or occasionally). The data were obtained by age group (18–29, 30–44, 45–64, and 65–99 years old) combined for East and West Germany. Current smoking prevalence which includes any combustible tobacco use, was 27.5% in 2012 in Germany [46], which was higher than every day or someday use of any combustible tobacco (22.2%) for that same year in the US [50]: (Germany vs. US: 34.7% vs. 21.3%

for ages 18–29; 34.5% vs. 27.0% for ages 30–44; 30.4% vs. 22.1% for ages 45–64, and 12.0% vs. 9.4% for ages 65+). We transformed age-group prevalence into individual age prevalence using the midpoints and then smoothing the estimates to represent the data distribution. (SAVM User Guide, sec 3.2.4). For Germany-SAVM, we apply the same prevalence for ages 18 to 22 as the prevalence at age 23 (the first midpoint in the 18–29 age group from GEDA) and the same prevalence for the upper age ranges (83–99 years) as the prevalence at age 82 (the last midpoint in the 65–99 age group from GEDA).

Smoking prevalence evolves based on initiation and cessation rates. These rates are set as a linear function of US rates and scaled for the initial modeling year’s country-specific/US smoking prevalence ratio. For Germany-SAVM, we applied the ratio of German to US smoking prevalence for ages 18–24 in 2012 to US initiation rates at all ages and the ratio of German to US smoking prevalence for ages 25–64 in 2012 to US cessation rates at all ages. Most relapse by former smokers occurs within 1 year after quitting. Relapse among those who quit for ≥2 years is less than 30% [51–54]. The model’s cessation rate collapse cessation and relapse into a measure of cessation net of relapse. SAVM cessation rate is based on former smokers who quit for at least 2 years and is meant to reflect permanent cessation [55]. (SAVM User Guide, sec 3.2.5).

To derive country-specific mortality rates by smoking status (never, current and former), SAVM multiplies US death rates by smoking status to the ratio of the country/US overall mortality rates. For smokers who quit before age 35, SAVM assumes the same mortality risks as never smokers [56–58]. SAVM’s US smoking status and mortality data (i.e., prevalence, mortality, and life expectancy)



**Fig. 1** Smoking and NVP Use Transitions in the No-NVP and NVP Scenarios

are obtained from the US National Cancer Institute, Cancer Intervention and Surveillance Modeling Network (CISNET) Lung group [56, 59–61]. The CISNET smoking status estimates are based on age-period-cohort models using data from the US National Health Interview Survey from 1965 to 2018: this captures trends in smoking before NVP use became more prevalent in the US [62]. Similarly, the CISNET mortality rates are based on mortality data through 2012 and smoking relative risks informed by data through the early 2000s, prior to the wide adoption of NVPs.

### NVP scenario

The NVP scenario projects the prevalence of current, former, and never smokers plus three new categories: current exclusive NVP users, former smokers using NVPs, and former NVP users (Fig. 1). Exclusive NVP users are those who initiate NVP use in the absence of smoking and those who switch to vaping from smoking before age 35. Former smokers using NVPs are those who quit cigarette use after age 34 and switch to exclusive NVP use. Dual users (of both cigarettes and NVPs) are considered current smokers and assumed to have the same mortality risks as exclusive cigarette users [12, 13] (Supplementary Table 1).

The NVP scenario considers five types of transition parameters: (1) switching from smoking to vaping, (2) vaping initiation, (3) smoking initiation, (4) vaping cessation, and (5) smoking cessation (Table 1). The model defines the last four transition parameters at levels proportional (i.e., as multipliers) to the respective transition parameters in the No-NVP scenario. The model allows NVP scenario transition parameters to vary over time by enabling a yearly exponential process (annual change rate) in the individual parameters (SAVM User Guide, sec 3.3.4).

For the Germany-SAVM, pre-loaded transitions rates and multipliers estimates were modified to account for the difference in NVP use rates between Germany and US. While any combustible use is higher in Germany than in the US, as indicated above, the opposite is observed for German NVP (e-cigarette) prevalence. In 2012, prevalence of NVP ever-use in the German population aged 15+ was 20.2% (95% CI 15.6–24.9%) [63]. In 2016–17, current NVP use prevalence in the German 14+ population was 1.9% (males 2.6% and females 1.3%) with the highest use in individuals ages 18–24 (3.5%) [64]. In contrast, in the US, by 2014, ever-NVP use in the 18+ population was 12.6%, and current NVP use was 3.7% [65]. In 2017, US current NVP use in adults 18+ was 2.8%, (males 3.2% and females 2.4%) with the highest use in the 18–24 age group (5.2%) [66].

Direct transitions from cigarette to exclusive NVP use occur through a constant NVP switching parameter, starting at the base year of the modeling period (e.g., Germany-SAVM at 2012 from the 2012–2060 period). Pre-loaded SAVM switching rates were derived from the US Population Assessment of Tobacco and Health (PATH) Study Waves 1–4 (2013–2017) (Supplementary Table 2). To account for differences between German and US smoking and NVP prevalence, we reduced SAVM's pre-loaded switching rates by 50% and allowed a 10% annual reduction rate starting in 2018.

The smoking and NVP initiation rates in the NVP scenario are developed by applying a separate cigarette and NVP use multiplier to the No-NVP smoking initiation rates. SAVM's US initiation multipliers are set as 75% for smoking and 50% for NVP use of the No-NVP smoking initiation rate for both genders and all ages and are assumed constant over time. The values are based on the rapid decline in US youth and young adult smoking since vaping increased [67–69]. However, the German population's smoking initiation starts at younger ages compared to the US. In 2012 in Germany, most of the initiation into regular smoking occurred between ages 15 to 17 [70, 71]. For that same year, the US reported the highest average age of daily cigarette use initiation between 18 and 21 years, followed by 15 to 17 years [72]. To account for these differences, the Germany-SAVM smoking and NVP initiation multipliers were set as 88 and 25%, respectively (Table 1).

Similar to initiation rates, the smoking and NVP cessation rates apply a pattern relative to smoking cessation in the No-NVP scenario. NVPs may influence smoking outcomes through cessation from both smoking and vaping, and through smoking initiation and switching. Considerable evidence indicates that NVPs may improve cessation from smoking and could be easier to quit than smoking [73–76]. Still, we set smoking and NVP cessation rates in the NVP scenario in the US-SAVM and the Germany-SAVM models to the same rate as the No-NVP smoking cessation rates (equal to 100% of the No-NVP smoking cessation rate) for both genders and all ages; they are assumed constant over time in this analysis but may be adjusted by the user to incorporate trends. We note that smokers may also quit smoking but continue to vape via the switching parameter. We have applied this method for simulation exercises for other countries, including Australia and Canada [77, 78].

An NVP *relative risk* multiplier specifies the NVP mortality risks *relative to* the excess mortality risk for current and former smokers (*current or former smoker death rate* – *never smoker death rate*). By default, SAVM specifies a constant current and former NVP users mortality risks at 5% of that of smoking for both genders at all ages, based

on estimates from a multi-criteria decision analysis [79] and an independent review [80]. Germany-SAVM applies an initial mortality relative risk of 5%. As this estimate may be debatable [81], we conduct sensitivity analyses and recommend that the user consider lower and upper-end mortality estimates between 2.5 and 50%.

### Model outputs

SAVM estimates public health impacts in terms of smoking-attributable deaths (SADs), smoking and vaping attributable deaths (SVADs), and life-years-lost (LYLs). Based on previous approaches [60, 82], SADs and SVADs are calculated by multiplying the excess mortality of current and former smokers or NVP users by the number of individuals in their smoking or NVP use category, and LYLs are calculated at each age by multiplying the number of SADs or SVADs by the life-years remaining of a never smoker. The public health impact of NVP use is evaluated as the difference in SVADs and LYLs between the No-NVP and NVP scenarios.

### Germany-SAVM validation and sensitivity analyses

Because prevalence rates for the same year often vary from survey to survey and are only available for limited years, we validate SAVM by comparing relative changes in smoking prevalence. The validation data used for the Germany-SAVM was over a specified period based on survey data availability. The Germany-SAVM was first validated by comparing relative changes in current smoking prevalence from the NVP scenario to those from Eurobarometer [83] from 2014 to 2020. Eurobarometer is a survey conducted yearly since 2014 by the European Union (EU) Institutions to monitor Europeans' attitudes towards various topics of interest. Current smokers in Eurobarometer were defined as "currently smoke" cigarettes, cigars, cigarillos, or a pipe. This current smoker definition matched well with the definition used in the GEDA survey. The model's smoking prevalence was also validated against the German Microcensus 2017 [84], a nationally representative survey that collects tobacco use data using similar methods and smoking definitions as the GEDA.

Finally, we validated NVP use by comparing the 2017 SAVM NVP use estimates against results from The German Study on Tobacco Use (Deutsche Befragung zum Rauchverhalten, [DEBRA]) 2016–2021 for both genders combined [64, 85]. DEBRA survey collects information on NVP use from nearly 2000 individuals ages 14+ every 2 months. This survey was chosen because data were available in successive years after NVPs became more widely used, and it allows comparisons by age group and gender.

We conducted sensitivity analyses with the NVP relative risks at 5 and 40% of the excess smoking risk and over plausible ranges of  $\pm 50\%$  of the NVP switching rates and initiation and cessation multiplier parameters. Recommended rates for sensitivity analyses are provided in Table 1.

## Germany-SAVM results

### Validation of smoking prevalence

Compared to Eurobarometer data, for ages 15+, Germany-SAVM projected that male (female) smoking prevalence declined from 29.1% (22.5%) in 2014 to 24.7% (19.6%) in 2020, while Eurobarometer reported a decline from 33.83% (20.8%) in 2014 to 27.6% (18.8%) in 2020. Over 2014–2020, Germany-SAVM projects an overall smaller relative reduction in smoking prevalence of 15.1% (12.9%) compared to 18.5% (9.9%) from the Eurobarometer. Eurobarometer data showed a more rapid decline in Germany's male smoking prevalence between 2014 and 2018 than SAVM, the period when NVP use was increasing. However, Germany's male smoking prevalence increased from 2018 to 2020, moving the relative declines in smoking prevalence much closer to SAVM projections. In contrast, Eurobarometer showed an increase in female smoking prevalence from 2014 to 2018, followed by a decrease from 2018 to 2020 (Supplementary Table 3).

We also validated SAVM smoking prevalence by age group against the German Microcensus for 2017. Germany-SAVM slightly overestimated the smoking prevalence for adults ages 18+ by a relative difference of 3.8% (SAVM 27.4% vs. Microcensus 26.4%) for males and a relative difference of 16% (SAVM 21.5% vs. Microcensus 18.6%) for females. For males ages 18 to 64 years, SAVM underpredicted smoking prevalence with relative differences between estimates ranging from 24.4% to  $-0.1\%$  but overestimated for males aged 65 to 70 with differences ranging from 18.4 to 37.1%. (Supplementary Fig. 1a) For females, in general, SAVM overestimated smoking prevalence with relative differences between SAVM and the Microcensus from 3.7 to 23.0% for ages 20 to 65 years. SAVM underestimated prevalence for individuals ages 18 to 20 years and 50 to 60 years. (Supplementary Fig. 1b). The largest relative differences between SAVM and the Microcensus were observed for ages 75+ for males and 70+ for females.

### Validation of NVP prevalence

For ages 18–24, the DEBRA survey and Germany-SAVM both reported current NVP prevalence at about 4% in 2016; DEBRA remained at 4% through 2018, while SAVM increased to 5.5% in 2019. After 2019, DEBRA NVP use fell to 2%, while SAVM increased to 6.5% in 2021. In 2016, for ages 25+, the NVP prevalence was 1% in SAVM

compared to 1.5% in DEBRA, and both were at 1.5% in 2019. However, in 2021, SAVM increased to 2.5%, while DEBRA fell to 1%. (Supplementary Figs. 2a and b).

**Public health impact under the baseline NVP compared to the no-NVP scenario**

Table 2 presents the Germany-SAVM results for all cohorts for the modeling period 2012–2060. In the No-NVP scenario, smoking prevalence among adult ages 18+ is projected to decline from 32.1 to 20.6% for males and from 24.7 to 16.1% for females from 2012 to 2060, which

is about 35% relative reduction in smoking combustible tobacco products for both genders. In the No-NVP scenario, from 2012 to 2060, SAVM projects 5.0 million SADs with 46.4 million LYs in males and 2.2 million SADs with 18.5 million LYs in females.

In the NVP scenario, SAVM projected that smoking prevalence for ages 18+ declines to 16.6% for males and 13.4% for females by 2060, which is about 48 and 46% relative reduction in smoking prevalence for males and females, respectively. Exclusive NVP prevalence increases between 2017 and 2060 from 1.3 to 5.5% for males and

**Table 2** The Germany SAVM model estimates for all cohorts (ages 18–99) with new births for 2012–2060. NVP risks at 5% those of excess smoking risks

| Year                               |                | 2012      | 2017      | 2040    | 2060    | Cumulative <sup>a</sup> |
|------------------------------------|----------------|-----------|-----------|---------|---------|-------------------------|
| <b>Male</b>                        |                |           |           |         |         |                         |
| <b>No-NVP scenario<sup>b</sup></b> | Smokers        | 32.1%     | 29.1%     | 22.5%   | 20.6%   | –                       |
|                                    | SADs           | 111,909   | 108,729   | 99,458  | 86,383  | 4,956,100               |
|                                    | LYs            | 1,171,679 | 1,189,823 | 890,229 | 671,585 | 46,425,200              |
| <b>NVP Scenario<sup>c</sup></b>    | Smokers        | 32.1%     | 27.4%     | 18.1%   | 16.6%   | –                       |
|                                    | NVP users      | 0.0%      | 1.3%      | 4.4%    | 5.5%    | –                       |
|                                    | FS-NVP users   | 0.0%      | 0.8%      | 1.3%    | 0.5%    | –                       |
|                                    | SVADs          | 111,909   | 107,342   | 94,707  | 79,977  | 4,757,770               |
|                                    | LYs            | 1,171,679 | 1,164,455 | 805,087 | 567,618 | 42,904,963              |
| <b>Net impact<sup>d</sup></b>      | Deaths averted | 0         | 1386      | 4751    | 6406    | 198,330                 |
|                                    | LYs averted    | 0         | 25,367    | 85,142  | 103,967 | 3,520,237               |
| <b>Female</b>                      |                |           |           |         |         |                         |
| <b>No-NVP scenario<sup>b</sup></b> | Smokers        | 24.7%     | 22.6%     | 17.7%   | 16.1%   | –                       |
|                                    | SADs           | 52,058    | 45,517    | 44,666  | 40,169  | 2,195,568               |
|                                    | LYs            | 440,936   | 441,049   | 369,645 | 267,812 | 18,462,657              |
| <b>NVP Scenario<sup>c</sup></b>    | Smokers        | 24.7%     | 21.5%     | 15.0%   | 13.4%   | –                       |
|                                    | NVP users      | 0.0%      | 0.7%      | 2.8%    | 3.9%    | –                       |
|                                    | FS-NVP users   | 0.0%      | 0.55%     | 0.8%    | 0.3%    | –                       |
|                                    | SVADs          | 52,058    | 44,611    | 42,352  | 37,872  | 2,101,907               |
|                                    | LYs            | 440,936   | 429,620   | 340,489 | 237,606 | 17,247,469              |
| <b>Net impact<sup>d</sup></b>      | Deaths averted | 0         | 906       | 2314    | 2296    | 93,661                  |
|                                    | LYs averted    | 0         | 11,428    | 29,156  | 30,206  | 1,215,187               |
| <b>Both genders</b>                |                |           |           |         |         |                         |
| <b>Net impact<sup>d</sup></b>      | Deaths averted | 0         | 2292      | 7065    | 8702    | 291,991                 |
|                                    | LYs averted    | 0         | 36,795    | 114,298 | 134,173 | 4,735,424               |
|                                    | Deaths averted | 0.0%      | 1.5%      | 4.9%    | 6.9%    | 4.1%                    |
|                                    | LYs averted    | 0.0%      | 2.3%      | 9.1%    | 14.3%   | 7.3%                    |

Results for the NVP scenario are estimated applying a 5% NVP mortality risk of that from smoking and with smoking initiation at 88%, NVP initiation at 25%, and cessation for smoking and NVP at 100% from that of the No-NVP scenario

NVP nicotine vaping product, FS-NVP former smokers nicotine vaping users, SADs smoking-attributable deaths, SVADs smoking and vaping attributable deaths, LYs Life years lost

<sup>a</sup> Cumulative results include the deaths and life-years lost, which are the sum of attributable deaths or life-years lost over the years 2012–2060

<sup>b</sup> No-NVP Scenario refers to values in the absence of NVP use

<sup>c</sup> NVP scenario refers to values with NVP use

<sup>d</sup> Net impact is the difference between the No-NVP Scenario and NVP Scenario in deaths averted (SADs-SVADs) and LYs

§ The relative net impact (%) in averted deaths and LYs are calculated for both genders as:

Deaths averted (%) = Deaths averted / SADs<sub>No-NVP</sub>; LYs averted (%) = LYs averted / LYs<sub>No-</sub>

from 0.7 to 3.9% for females. From 2012 to 2060, SAVM projects 4.8 million SVADs with 42.9 million LYLs in males and 2.1 million SVADs with 17.3 million LYLs in females in the NVP scenario.

Compared to the No-NVP scenario, the estimated public health net impact of NVPs by 2060 is a reduction in relative terms of the smoking prevalence of 19% [(16.6–20.6)/20.6] for males and 17% [(13.4–16.1)/16.1] for females. In addition, the use of NVPs is projected to avert 0.3 million premature deaths and secure 4.7 million life-years by 2060, representing relative reductions of 4.1% in cumulative premature deaths and 7.3% in LYLs in German population.

**Sensitivity analysis of NVP transition parameters**


Compared to the 0.3 million SVADs and 4.7 million LYLs between 2012 and 2060 under the base case NVP scenario, averted SVADs and LYLs fell to 0.17 million and 2.8 million, respectively, with a 40% relative excess mortality risk while holding transition parameters constant. Less conservative scenarios such as a 15% relative risk projected 0.25 million fewer deaths and a 25% relative risk projected 0.22 million fewer deaths. However, with more pessimistic scenarios such as 50% relative risk (0.13 million SAVDs averted), the model shows that a point of inflection is reached after 2040 where the increase in deaths averted is minimal. (Fig. 2).

When applying variations in transition parameters, SAVM projected the highest number of averted SVADs

and LYLs with the smoking cessation multiplier at 150% of its original value, 0.97 million SVADs and 12.0 million LYLs with a 5% excess NVP risk. These estimates decreased to 0.89 million SVADS and 10.1 million LYLs with a 40% excess NVP risk. Large reductions were observed when increasing the switching rate by 150% with a 10% annual decay and reducing smoking initiation by 50%. In contrast, Germany-SAVM estimated an increase in SVADs and LYLs when increasing the cigarette initiation multiplier by 150% and reducing the switching rate and cessation multiplier by 50% (Tables 3 and 4).

**Discussion**

The SAVM provides users with a tool to examine the potential impact of NVP use on smoking and vaping behaviors and subsequent mortality outcomes. We developed the SAVM to provide a model that can be applied by those less experienced in modeling. The population, health outcomes, and smoking prevalence data needed for the model are minimal and these data can generally be found through publicly available sources. We built the Germany-SAVM using publicly available country specific data from the WHO and United Nations databases and smoking prevalence from the GEDA, a nationally representative survey. Using these three data sources, SAVM’s formulas allow us to transform US pre-loaded model parameters into Germany-specific inputs and estimate the potential public health impact of NVP use for the German population. Although the SAVM is accessible to



**Fig. 2** Estimated averted smoking and vaping-attributable deaths applying different values for the NVP excess mortality risk. Results from the sensitivity analysis for both genders ages 8–99 years from 2012 to 2060



**Table 3** Estimated adverted smoking-attributable deaths applying different values for the NVP Scenario input parameters. Results from the sensitivity analysis for both genders ages 8–99 years from 2012 to 2060

| Scenario  | NVP relative risk <sup>a</sup><br>(Risk <sub>NVP</sub> )=5% |  | NVP relative risk <sup>a</sup><br>(Risk <sub>NVP</sub> )=40% |  | Relative Change<br>5% vs. 40% <sup>d</sup> |
|---|---|--|--|--|--|
| <b>No-NVP Scenario</b>  | <b>Total SVADs</b>  |  | <b>Total SVADs</b>   |  | –  |
|   | 7,151,668   |  | 7,151,668  |  | –  |
| <b>NVP Scenario with parameter changes from base model</b>    | <b>Averted SVADs<sup>b</sup></b>                            | <b>Relative Difference (vs. base model estimate)<sup>c</sup></b> | <b>Averted SVADs<sup>b</sup></b>                             | <b>Relative Difference (vs. base model estimate)<sup>c</sup></b> | –  |
| Base model estimate <sup>e</sup>                              | 291,991   | 0.0%   | 167,127  | 0.0%   | –42.8%                                     |
| Switching rate and annual change                              |   |  |  |  |  |
| 50% of switching <sup>f</sup> , 10% annual decay <sup>g</sup> | 160,588   | –45.0%   | 89,496   | –46.5%   | –44.3%                                     |
| 150% of switching, 10% annual decay                           | 414,852   | 42.1%  | 239,723  | 43.4%  | –42.2%                                     |
| Initiation rate multipliers and annual change                 |   |  |  |  |  |
| 50% smoking initiation <sup>h</sup> , no annual decay         | 345,646   | 18.4%  | 222,726  | 33.3%  | –35.6%                                     |
| 150% smoking initiation, no annual decay                      | 245,410   | –16.0%   | 118,780  | –28.9%   | –51.6%                                     |
| 50% NVP initiation <sup>i</sup> , no annual decay             | 290,608   | –0.5%  | 172,263  | 3.1%   | –40.7%                                     |
| 150% NVP initiation, no annual decay                          | 293,338   | 0.5%   | 162,200  | –2.9%  | –44.7%                                     |
| Cessation rate multipliers and annual change                  |   |  |  |  |  |
| 50% of smoking cessation multiplier <sup>j</sup>              | –769,218  | –363.4%  | –906,453   | –642.4%  | 17.8%                                      |
| 150% of smoking cessation multiplier                          | 972,300   | 233.0%   | 857,132  | 412.9%   | –11.8%                                     |
| 50% of NVP cessation <sup>k</sup> multiplier                  | 284,899   | –2.4%  | 116,621  | –30.2%   | –59.1%                                     |
| 150% of NVP cessation multiplier                              | 296,656   | 1.6%   | 200,873  | 20.2%  | –32.3%                                     |

NVP nicotine vaping product, Smoking and Vaping attributable deaths (SVADs)

<sup>a</sup> The NVP relative risk multiplier is the mortality risk of NVPs as a percentage of the excess mortality risk of smoking

<sup>b</sup> The absolute reduction in SVADs in the NVP Scenario compared with the No-NVP Scenario over 2012–2060

<sup>c</sup> The relative percent change in averted SVADs for each NVP Scenario is compared with the initial NVP Scenario (best estimate). A negative (positive) value implies that changing the parameter will decrease (increase) the averted SAVDs in the specific scenario relative to averted SVADs in the initial NVP Scenario

<sup>d</sup> The relative percent change in averted LYLs between scenarios with NVP risk multipliers of 5% vs. 40% is calculated as (Averted SVADs with 40% NVP risk – Averted SVADs with 5% NVP risk)/Averted SVADs with 5% NVP risk

<sup>e</sup> The initial values for each input parameter in the NVP Scenario are as follows. NVP switching rate for males (females): 4% (2.5%) for ages 24 and below, 2.5% (2.0%) for ages 25–34, 2.5% (1.6%) for age 35–44, 1.3% (1.4%) for ages 45–54, 1.2% (1.4%) for ages 55–64, and 0.6% (1.0%) for ages 65 and above; smoking initiation multiplier = 88%; NVP initiation multiplier = 25%; Smoking cessation multiplier = NVP cessation multiplier = 100%

<sup>f</sup> NVP switching rate is the annual rate at which current smokers switch to NVPs

<sup>g</sup> Annual decay rate is the exponential rate of decline in switching rates over time

<sup>h</sup> Smoking initiation multiplier is relative to smoking initiation in the No-NVP Scenario

<sup>i</sup> NVP initiation multiplier is relative to smoking initiation rates in the No-NVP Scenario

<sup>j</sup> Smoking cessation multiplier is relative to smoking cessation in the No-NVP Scenario

<sup>k</sup> NVP cessation multiplier is relative to smoking cessation rates in the No-NVP Scenario

people who do not have much experience in simulation modeling, it also allows advanced modelers to modify underlying input data, equations, and its structures [44]. Nonetheless, the simplicity and transparency of SAVM has some drawbacks such as its inability to account for interactions between other risk factors or products that could influence the outcome and its limited number of possible outcomes.

Germany-SAVM estimated a reduction of 4.7 million life-years lost and almost 300,000 deaths averted associated with NVP use. However, the estimates should be viewed cautiously since model validation indicated that smoking and NVP prevalence were overestimated,

especially for ages 18–24 female, and thus may underestimate the impacts of NVP since smoking prevalence has been overestimated.

The lack of better validation may reflect uncertainty about German tobacco use behaviors, particularly regarding switching from cigarette to NVPs or other products, since survey data to validate the model was limited. Ideally, SAVM estimates should be compared against various years of nationally representative smoking and NVP prevalence by age group and gender from the same survey, preferably the one used as input. After 2012, GEDA only collected information for 2019/2020, the database was not publicly available at

**Table 4** Estimated life-years saved applying different values for the NVP Scenario input parameters. Results from the sensitivity analysis for both genders 18–99 from 2012 to 2060

| Scenario  | NVP relative risk <sup>a</sup> (Risk <sub>NVP</sub> )=5% |  | NVP relative risk <sup>a</sup> (Risk <sub>NVP</sub> )=40% |  | Relative Change 5% vs. 40% |
|---|--|--|---|--|----------------------------|
| <b>No-NVP Scenario</b>  | <b>Total LYLs</b>  |  | <b>Total LYLs</b>   |  | –                          |
|   | 64,887,857   |  | 64,887,857  |  | –                          |
| <b>NVP Scenario with parameter changes from base model</b>    | <b>Averted LYLs<sup>b</sup></b>                          | <b>Relative Difference<sup>c</sup></b> | <b>Averted LYLs<sup>b</sup></b>                           | <b>Relative Difference<sup>c</sup></b> | –                          |
| Base model estimate <sup>e</sup>                              | 4,735,424  | 0.0%                                   | 2,745,088   | 0.0%                                   | –42.8%                     |
| Switching rate and annual change                              |  |  |   |  |                            |
| 50% of switching <sup>f</sup> , 10% annual decay <sup>g</sup> | 2,737,897  | –42.2%                                 | 1,517,938   | –44.7%                                 | –44.6%                     |
| 150% of switching, 10% annual decay                           | 6,589,927  | 39.2%                                  | 3,884,888   | 41.5%                                  | –41.0%                     |
| Initiation rate multipliers and annual change                 |  |  |   |  |                            |
| 50% smoking initiation <sup>h</sup> , no annual decay         | 6,282,285  | 32.7%                                  | 4,343,035   | 58.2%                                  | –30.9%                     |
| 150% smoking initiation, no annual decay                      | 3,412,112  | –27.9%                                 | 1,375,850   | –49.9%                                 | –59.7%                     |
| 50% NVP initiation <sup>i</sup> , no annual decay             | 4,688,798  | –1.0%                                  | 2,885,784   | 5.1%                                   | –38.5%                     |
| 150% NVP initiation, no annual decay                          | 4,780,843  | 1.0%                                   | 2,610,916   | –4.9%                                  | –45.4%                     |
| Cessation rate multipliers and annual change                  |  |  |   |  |                            |
| 50% of smoking cessation multiplier <sup>j</sup>              | –5,390,126   | –213.8%                                | –7,516,335  | –373.8%                                | 39.4%                      |
| 150% of smoking cessation multiplier                          | 11,957,832   | 152.5%                                 | 10,081,676  | 267.3%                                 | –15.7%                     |
| 50% of NVP cessation <sup>k</sup> multiplier                  | 4,658,618  | –1.6%                                  | 2,156,853   | –21.4%                                 | –53.7%                     |
| 150% of NVP cessation multiplier                              | 4,791,564  | 1.2%                                   | 3,177,221   | 15.7%                                  | –33.7%                     |

NVP nicotine vaping product, LYLs life-years lost

<sup>a</sup> The NVP relative risk multiplier is the mortality risk of NVPs as a percentage of the excess mortality risk of smoking

<sup>b</sup> The absolute reduction in life-years lost in the NVP Scenario compared with the No-NVP Scenario over 2012–2060

<sup>c</sup> The relative percent change in averted LYLs for each NVP Scenario is compared with the initial NVP Scenario (best estimate). A negative (positive) value implies that changing the parameter will decrease (increase) the averted LYLs in the specific scenario relative to averted LYLs in the initial NVP Scenario

<sup>d</sup> The relative percent change in averted LYLs between scenarios with NVP risk multipliers of 5% vs. 40% is calculated as (Averted LYLs with 40% NVP risk – Averted LYLs with 5% NVP risk)/Averted LYLs with 5% NVP risk

<sup>e</sup> The initial values for each input parameter in the NVP Scenario are as follows. NVP switching rate for males (females): 4% (2.5%) for ages 24 and below, 2.5% (2.0%) for ages 25–34, 2.5% (1.6%) for age 35–44, 1.3% (1.4%) for ages 45–54, 1.2% (1.4%) for ages 55–64, and 0.6% (1.0%) for ages 65 and above; smoking initiation multiplier = 88%; NVP initiation multiplier = 25%; Smoking cessation multiplier = NVP cessation multiplier = 100%

<sup>f</sup> NVP switching rate is the annual rate at which current smokers switch to NVPs

<sup>g</sup> Annual decay rate is the exponential rate of decline in switching rates over time

<sup>h</sup> Smoking initiation multiplier is relative to smoking initiation in the No-NVP Scenario

<sup>i</sup> NVP initiation multiplier is relative to smoking initiation rates in the No-NVP Scenario

<sup>j</sup> Smoking cessation multiplier is relative to smoking cessation in the No-NVP Scenario

<sup>k</sup> NVP cessation multiplier is relative to smoking cessation rates in the No-NVP Scenario

the time of this study, and publications did not report the necessary data. We were also unable to find other German nationally representative population surveys with the required characteristics. Consequently, we validated the Germany-SAVM against three surveys: the Microcensus, Eurobarometer, and DEBRA. The Microcensus and Eurobarometer allowed us to compare smoking population estimates by age group and gender. The Microcensus is a nationally representative survey, and its large sample size enables more accurate age group comparisons. Eurobarometer provided

consistent yearly post-NVP era smoking data. Because these surveys did not provide sufficient NVP use data for validation, we decided to use the DEBRA survey to validate Germany-SAVM NVP estimates. DEBRA is a nationally-representative household survey that permits comparison across different years of NVP use data and limited age groups. Continuous data, preferably longitudinal data is needed to better understand the relevant transitions. Application of the model may help policy makers recognize the limitations of

current surveys for effective monitoring of product use behaviors.

### Limitations

SAVM's accuracy depends on the availability of tobacco surveillance data and how the data exhibit changes in smoking behaviors associated with the country's tobacco regulations. Germany's limited smoking and NVP data sources, and their low frequency of data collection on tobacco control, restricted our ability to adapt Germany-SAVM to represent product use trends that reflect the current German regulatory scenario. SAVM rescaled US data to adapt to other countries, differences between collecting data methods between countries may influence model validation. German surveys smoking prevalence definition includes every day or occasional use of any combustible tobacco, and US-SAVM current smoking definition refers to individuals who have smoked at least 100 cigarettes in their lifetime. However, 2010 data reported that 83% of females and 76% of males of all combustible tobacco users (smokers) in Germany are cigarette users [86]. Still, even same product use definition can produce different population estimates for the same year of data collection [87]. Our analysis did not consider heated tobacco products, although their role appears minor [88, 89]. The failure to accurately estimate the decline in NVP use and the leveling off from combustible tobacco use since 2018 may also reflect a failure to incorporate changes in tobacco regulations into the model. Since 2018, considerable publicity has been devoted to the potential harms of NVPs, and German states and the federal government have implemented stricter NVP regulations. This has been augmented by the passage of the 2021 Tobacco Duty Modernization Act (Tabaksteuermodernisierungsgesetz) [38], which increased the excise tax rates for cigarettes, NVPs, and heated tobacco products.

The SAVM results should also be evaluated in the context of the model's assumptions and data inputs (see Supplementary Table 5). For instance, SAVM assumes that former smokers' mortality risk is dependent on age and birth cohort year [90, 91], but it has been observed that mortality risk from smoking to be inversely associated with quit years falling close to the same level of risk as never smokers after 10 years of quit [92–96]. Further, NVP is a novel product and there is a lack of evidence on long-term impact of NVP use, dual usage or quit years on mortality or associated chronic disease development. We assume that the risk for former NVP users is reduced by the ratio of former to current smoker risk, using the same risk of 5% for former and current NVP users. NVP mortality risk can be updated as evidence evolves.

The No-NVP scenario refers to data through 2012 and assumes trends in smoking up until that year would have continued in the absence of NVPs. However, the counterfactual is unknown; post-2012 smoking prevalence declines may have accelerated or decelerated without NVPs at a different rate in Germany than in the US. The model relies on underlying US smoking trends to project future smoking and mortality rates for other countries. For the Germany-SAVM, we modified the transition parameters to adapt to German tobacco use patterns. Still, the shortage of information on transitions between smoking and NVP use for the German population and the effect of tobacco control policies on behaviors may have impaired Germany-SAVM from reflecting pre-NVP trends.

Parameters in the NVP scenario may also affect the validity of the model. Compared to cigarettes, NVPs are newer products with less empirical evidence about their health effects and usage/transition patterns [97, 98]. The true extent of NVP health risks is not well understood [81]. We performed sensitivity analyses increasing the NVP excess risk parameter from 5, 15, 25, 40 and 50%, to consider a range of potential effects. We observed that a conservative approach of 15% % NVP risk (Supplementary Table 4), provides estimates similar to the 5% risk case. When applying 40% or higher, the number of deaths averted becomes stagnant (Fig. 2).

In addition, NVPs' disruption of the tobacco landscape depends on each country's existing social and regulatory environment, for NVPs and cigarettes and other tobacco products [99, 100]. Consequently, patterns of future NVP use are challenging to predict because they depend on policies that encourage the growth (or decline) of the NVP market. SAVM users are encouraged to conduct sensitivity analyses on NVP risks and the NVP scenario transition rates and multipliers to investigate the influence of NVP use under a range of plausible parameters. We suggest such ranges in the SAVM User Guide [44].

The SAVM treats those who experimented with or use NVPs only occasionally as never smokers. It also treats current smokers who use NVPs temporarily (as a dual user or exclusive user) and quit both cigarettes and NVPs products within 2 years as former smokers. The potential gateway effect of vaping to smoking occurs through the net NVP and smoking initiation. Because transitions to dual use are often temporary [101–104] and dual users have risks comparable to smokers [12, 13], we chose not to distinguish between exclusive smokers and dual users in the NVP scenario. This assumption implies that dual users will have the same cessation and switching patterns with the same health risks as exclusive smokers. However, the sensitivity analysis allows to consider modifications

in smoking behavior parameters that could implicitly allow the effect of dual use. Should research demonstrate dual users to have a different health profile from exclusive smokers, the SAVM can be easily modified accordingly.

The SAVM is designed to simulate patterns of switching and substitution between cigarettes and NVPs. The model structure and design are flexible enough to simulate their specific use patterns if the user aims to model a specific NVP or any new emerging tobacco products, such as heated tobacco product (HTP) [86–88]. When including other tobacco products use into the current SAVM, data-driven parameters for NVPs may not be generalizable to other products. One way to handle such case is that for example, the user may include NVPs and HTPs in the same category but considerable attention must be made to the complex substitution patterns between cigarettes, NVPs, and HTPs, and differences in risk levels [105–107].

Policymakers and researchers can use SAVM to assess the relationship between potential reduced-harm product use and cigarette smoking and evaluate its impact on public health. Following up on Germany's tobacco control progress, regular monitoring is essential, particularly now as Germany will undergo important changes in tobacco regulation. Germany is one considered a high burden country from tobacco use [108]. It is one of ten countries with the largest number of smokers in Europe and the prevalence of smokers and NVP users has remained relatively stable. Based on the Tobacco Control Scale, in 2019 Germany ranked last in Europe in tobacco control [109]. Germany ratified the World Health Organization Framework Convention on Tobacco Control (WHO-FCTC) [110] but they have yet to implement most of the recommended cigarette-oriented policies [111].

However, in 2021, Germany released the Strategy for Tobacco-Free Germany 2040 (Strategie für ein tabakfreies Deutschland 2040), which proposed the progressive implementation of 10 measures to reduce the use of tobacco, NVPs and other related products to  $\leq 5\%$  of adults and  $\leq 2\%$  of adolescents by 2040 [108]. The Germany-SAVM could be a valuable tool to the country in assessing and monitoring policy progress towards proposed intermediate and final targets. As new information is obtained, the model can be modified to guide regulations.

In conclusion, simulation models play an increasingly important role in tobacco control policy decisions, so models must be readily available, easily adaptable, and transparent. SAVM is a generic heuristic simulation tool that is easily adaptable to different countries, has minimal data requirements, and can be

used by non-expert modelers. Its framework allows for updates and data modifications to keep up with the scientific advancements in the study of tobacco and NVP use. SAVM-produced estimates can help researchers, policymakers, and other public health stakeholders to analyze the potential population health effects of NVP use. Its specific characteristics allow the user to understand the model better, and synthesize and translate data into a modeling framework that can support future interventions and the the outcomes into more effective interventions to achieve tobacco control goals.

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12889-023-17152-y>.

**Additional file 1: Supplementary Table 1.** Smoking and Vaping Model, recommended definitions for cigarette use and NVPs use status. **Supplementary Table 2.** SAVM cigarette to nicotine and vaping product use switching rates from the US Population Assessment of Tobacco and Health (PATH) survey 2013–2017. **Supplementary Table 3.** Smoking prevalence (%), validation of Germany-SAVM against the Eurobarometer-Germany, by age and gender, 2014–2020. **Supplementary Figure 1a.** Validation of Germany-SAVM male smoking prevalence vs. German Microcensus 2017. **Supplementary Figure 1b.** Validation of Germany-SAVM female smoking prevalence vs. German Microcensus 2017. **Supplementary Figure 2a.** Validation of Germany-SAVM NVP use prevalence vs. the German Study on Tobacco Use (DEBRA). Results for adults ages 18 to 24 years. **Supplementary Figure 2b.** Validation of Germany-SAVM NVP use prevalence vs. the German Study on Tobacco Use (DEBRA). Results for adults ages 25 and above. **Supplementary Table 4.** The Germany SAVM model estimates for all cohorts (ages 18–99) with new births for 2012–2060. NVP risks at 15% those of excess smoking risks. **Supplementary Table 5.** The Smoking and Vaping Model modeling assumption and its implications.

### Acknowledgments

We would like to thank participants of talks given to the TCORS- Center for the Assessment of Tobacco Regulations (CAsToR) and the International Tobacco Control (ITC) groups. Special thanks go to Ronald Borland, Michael Cummings, and Bryan Heckman.

### Authors' contributions

LMSR and DTL wrote the original manuscript, and YL and ZY conducted the analyses and edited the Methods section. JT, AL, NT, JJ,MI and RM helped edit the paper. All authors reviewed the final version of the manuscript.

### Funding

Dr. Levy received funding from the National Cancer Institute ITC grant, P01CA200512. Dr. Meza acknowledges support from this Rogel Scholar award from the Rogel Cancer Center, University of Michigan.

### Availability of data and materials

Data used to parameterize the model are publicly available [https://www.gbe-bund.de/gbe/lpkg\\_olap\\_tables.prc\\_set\\_orientation?p\\_uid=gastd&p\\_aid=49431685&p\\_sprache=E&p\\_help=2&p\\_indnr=746&p\\_ansnr=95402022&p\\_version=2&D.000=1&D.001=2&D.002=2&D.003=1&D.355=1&D.371=3](https://www.gbe-bund.de/gbe/lpkg_olap_tables.prc_set_orientation?p_uid=gastd&p_aid=49431685&p_sprache=E&p_help=2&p_indnr=746&p_ansnr=95402022&p_version=2&D.000=1&D.001=2&D.002=2&D.003=1&D.355=1&D.371=3).

The SAVM package and User Guide are made available to the public by the University of Michigan and Georgetown University-Tobacco Center of Regulatory Science (TCORS)-Center for the Assessment of Tobacco Regulation (CAsToR) group upon request at:

[https://tcors.umich.edu/Resources\\_Download.php?FileType=SAV\\_Model](https://tcors.umich.edu/Resources_Download.php?FileType=SAV_Model)

## Declarations

### Ethics approval and consent to participate

This study uses publicly available data sets. No ethical approval was required. This study uses publicly available anonymized data sets. Informed consent was not required.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no competing interests.

### Author details

<sup>1</sup>Lombardi Comprehensive Cancer Center, Georgetown University, 2115 Wisconsin Ave, suite 300, Washington, DC 20007, USA. <sup>2</sup>School of Public Health, Yale University, New Haven, CT, USA. <sup>3</sup>Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA. <sup>4</sup>Integrative Oncology, BC Cancer Research Institute, British Columbia, Canada. <sup>5</sup>School of Population and Public Health, University of British Columbia, Columbia, Canada.

Received: 8 August 2022 Accepted: 4 November 2023

Published online: 21 November 2023

## References

- Besaratinia A, Tommasi S. Vaping: a growing global health concern. *EClinicalMedicine*. 2019;17:100208.
- World Health Organization. WHO Report on the Global Health Epidemic 2019: Offer to help Quit Tobacco. 2019. Geneva, Switzerland: World Health Organization.
- Carballo RS, et al. Quit methods used by US adult Cigarette smokers, 2014–2016. *Prev Chronic Dis*. 2017;14:E32.
- Giovenco DP, Delnevo CD. Prevalence of population smoking cessation by electronic cigarette use status in a national sample of recent smokers. *Addict Behav*. 2018;76:129–34.
- Filippidis FT, et al. Two-year trends and predictors of e-cigarette use in 27 European Union member states. *Tob Control*. 2017;26(1):98–104.
- Ferkol TW, et al. Electronic cigarette use in youths: a position statement of the forum of international respiratory societies. *Eur Respir J*. 2018;51(5)
- Hecht SS, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-Cigarette users versus Cigarette smokers. *Nicotine Tob Res*. 2014;
- Royal College of Physicians. *Nicotine without smoke: Tobacco harm reduction*. London: RCP; 2016.
- Goniewicz ML, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control*. 2014;23(2):133–9.
- Goniewicz ML, et al. Exposure to nicotine and selected toxicants in Cigarette smokers who switched to electronic cigarettes: a longitudinal within-subjects observational study. *Nicotine Tob Res*. 2017;19(2):160–7.
- Ratajczak A, et al. How close are we to definitively identifying the respiratory health effects of e-cigarettes? *Expert Rev Respir Med*. 2018;12(7):549–56.
- Czoli CD, et al. Biomarkers of exposure among "dual users" of Tobacco cigarettes and electronic cigarettes in Canada. *Nicotine Tob Res*. 2019;21(9):1259–66.
- Shahab L, et al. Nicotine, carcinogen, and toxin exposure in long-term E-Cigarette and nicotine replacement therapy users: a cross-sectional study. *Ann Intern Med*. 2017;166(6):390–400.
- Farsalinos KE, et al. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. *Sci Rep*. 2014;4:4133.
- DeVito EE, Krishnan-Sarin S. E-cigarettes: impact of E-liquid components and device characteristics on nicotine exposure. *Curr Neuropharmacol*. 2018;16(4):438–59.
- Yingst JM, et al. Nicotine absorption during electronic cigarette use among regular users. *PLoS One*. 2019;14(7):e0220300.
- Wagener TL, et al. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. *Tob Control*. 2017;26(e1):e23–8.
- Glasser AM, et al. Overview of electronic nicotine delivery systems: a systematic review. *Am J Prev Med*. 2017;52(2):e33–66.
- Levy DT, et al. A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products. *Addiction*. 2017;112(1):8–17.
- Gredner T, et al. Impact of Tobacco Control policies on Smoking-Related Cancer incidence in Germany 2020 to 2050—a simulation study. *Cancer Epidemiol Biomark Prev*. 2020;29(7):1413–22.
- Levy DT, et al. The benefits from complying with the framework convention on tobacco control: a SimSmoke analysis of 15 European nations. *Health Policy Plan*. 2014;29(8):1031–42.
- Final Report-PPACTE (Pricing policies and control of tobacco in Europe). 2013 [cited 2023 August 09]; Available from: <https://cordis.europa.eu/project/id/223323/reporting/de>.
- Chugh A, et al. The global impact of tobacco control policies on smokeless tobacco use: a systematic review. *Lancet Glob Health*. 2023;11(6):e953–68.
- Institute for global Tobacco Control. E-Cigarette policy Scan. 2019 [cited 2019 December 9]; Available from: <https://www.globaltobaccocontrol.org/e-cigarette/country-laws/view>.
- Kennedy RD, et al. Global approaches to regulating electronic cigarettes. *Tob Control*. 2017;26(4):440–5.
- Bachand AM, Sulsky SI, Curtin GM. Assessing the likelihood and magnitude of a population health benefit following the market introduction of a modified-risk Tobacco product: enhancements to the dynamic population modeler, DPM(+1). *Risk Anal*. 2018;38(1):151–62.
- Cherng ST, et al. Modeling the effects of E-cigarettes on Smoking behavior: implications for future adult Smoking prevalence. *Epidemiology*. 2016;27(6):819–26.
- Cobb CO, et al. Markov modeling to estimate the population impact of emerging Tobacco products: a proof-of-concept study. *Tob Regul Sci*. 2015;1(2):129–41.
- Hill A, Camacho OM. A system dynamics modelling approach to assess the impact of launching a new nicotine product on population health outcomes. *Regul Toxicol Pharmacol*. 2017;86:265–78.
- Kalkhoran S, Glantz SA. Modeling the health effects of expanding e-Cigarette sales in the United States and United Kingdom: a Monte Carlo analysis. *JAMA Intern Med*. 2015;175(10):1671–80.
- Poland B, Teischinger F. Population modeling of modified risk Tobacco products accounting for Smoking reduction and gradual transitions of relative risk. *Nicotine Tob Res*. 2017;19(11):1277–83.
- Soneji SS, et al. Quantifying population-level health benefits and harms of e-cigarette use in the United States. *PLoS One*. 2018;13(3):e0193328.
- Weitkunat R, et al. A novel approach to assess the population health impact of introducing a modified risk Tobacco product. *Regul Toxicol Pharmacol*. 2015;72(1):87–93.
- Warner KE, Mendez D. E-cigarettes: comparing the possible Risks of increasing Smoking initiation with the potential benefits of increasing Smoking cessation. *Nicotine Tob Res*. 2019;21(1):41–7.
- Levy DT, et al. The application of a decision-theoretic model to estimate the public health impact of vaporized nicotine product initiation in the United States. *Nicotine Tob Res*. 2017;19(2):149–59.
- Levy DT, et al. Potential deaths averted in USA by replacing cigarettes with e-cigarettes. *Tob Control*. 2018;27(1):18–25.
- Levy DT, et al. Public health implications of vaping in the USA: the smoking and vaping simulation model. *Popul Health Metrics*. 2021;19(1):19.
- Gesetz zur Modernisierung des Tabaksteuerrechts (Tabaksteuermodernisierungsgesetz - TabStMoG). 2021 [cited 2021 November 1st]; Available from: [https://www.bundesfinanzministerium.de/Content/DE/Gesetzestexte/Gesetze\\_Gesetzesvorhaben/Abteilungen/Abteilung\\_lung\\_III/19\\_Legislaturperiode/2021-08-17-TabStMoG/0-Gesetz.html](https://www.bundesfinanzministerium.de/Content/DE/Gesetzestexte/Gesetze_Gesetzesvorhaben/Abteilungen/Abteilung_lung_III/19_Legislaturperiode/2021-08-17-TabStMoG/0-Gesetz.html).
- Ettelt S, Hawkins B. Scientific controversy, issue salience, and E-Cigarette regulation: a comparative study of policy debates in Germany and England. *Eur Policy Anal*. 2018;4:255–74.
- Levy DT, et al. Germany SimSmoke: the effect of tobacco control policies on future smoking prevalence and smoking-attributable deaths in Germany. *Nicotine Tob Res*. 2013;15(2):465–73.
- Sonntag D, et al. German EstSmoke: estimating adult smoking-related costs and consequences of smoking cessation for Germany. *Addiction*. 2018;113(1):125–36.

42. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019 - Special Aggregates, Online Edition. Rev. 1. [cited 2021 July 20]; Available from: <https://population.un.org/wpp/Download/SpecialAggregates/Geographical/>.
43. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019, Online Edition. Rev. 1. 2019 [cited 2021 July 26]; Available from: <https://population.un.org/wpp/Download/Standard/Mortality/>.
44. Levy, D., et al. The Smoking and Vaping Model (SAVM) and Manual. 2021 [cited 2021 July 24]; Available from: [https://tcors.umich.edu/Resources\\_Download.php?FileType=SAV\\_Model](https://tcors.umich.edu/Resources_Download.php?FileType=SAV_Model).
45. CISNET. 2016, "Smoking Histories". . [cited 2020 January 2020]; Available from: (<https://resources.cisnet.cancer.gov/projects/>).
46. Robert Koch Institute. Gesundheit in Deutschland Aktuell (GEDA, German Health Update) 2012 [cited 2021 June 16]; Available from: [https://www.gbe-bund.de/gbe/!pkg\\_olap\\_tables.prc\\_set\\_orientation?p\\_uid=gastd&p\\_aid=49431685&p\\_sprache=E&p\\_help=2&p\\_indnr=746&p\\_ansnr=95402022&p\\_version=2&D.000=1&D.001=2&D.002=2&D.003=1&D.355=1&D.371=3](https://www.gbe-bund.de/gbe/!pkg_olap_tables.prc_set_orientation?p_uid=gastd&p_aid=49431685&p_sprache=E&p_help=2&p_indnr=746&p_ansnr=95402022&p_version=2&D.000=1&D.001=2&D.002=2&D.003=1&D.355=1&D.371=3).
47. Farsalinos KE, et al. Electronic cigarette use in the European Union: analysis of a representative sample of 27 460 Europeans from 28 countries. *Addiction*. 2016;111(11):2032–40.
48. Morgenstern M, et al. E-cigarettes and the use of conventional cigarettes. *Dtsch Arztebl Int*. 2018;115(14):243–8.
49. Lehmann K, Kuhn S, Reimer J. Electronic cigarettes in Germany: patterns of use and perceived health improvement. *Eur Addict Res*. 2017;23(3):136–47.
50. Agaku IT, et al. Tobacco product use among adults—United States, 2012–2013. *MMWR Morb Mortal Wkly Rep*. 2014;63(25):542–7.
51. Pesce G, et al. Time and age trends in smoking cessation in Europe. *PLoS One*. 2019;14(2):e0211976.
52. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction*. 2004;99(1):29–38.
53. Garcia-Rodriguez O, et al. Probability and predictors of relapse to smoking: results of the National Epidemiologic Survey on alcohol and Related conditions (NESARC). *Drug Alcohol Depend*. 2013;132(3):479–85.
54. Lee SE, et al. Patterns and predictors of smoking relapse among inpatient smoking intervention participants: a 1-year follow-up study in Korea. *Epidemiol Health*. 2021;43:e2021043.
55. Tobacco Control Simulation Models- Appendix 15.1, in *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*, National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health., Editor. 2014, Centers for Disease Control and Prevention: Atlanta (GA).
56. Holford TR, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964–2012. *JAMA*. 2014;311(2):164–71.
57. Burns D, Garfinkel L, Samet J. Changes in Cigarette-Related Disease Risks and Their Implication for Prevention and Control. *Smoking and Tobacco Control Monograph 8*. Bethesda, MD: National Institutes of Health, National Cancer Institute; 1997.
58. Jha P, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med*. 2013;368(4):341–50.
59. Rosenberg MA, et al. Chapter 3: cohort life tables by smoking status, removing lung cancer as a cause of death. *Risk Anal*. 2012;32(Suppl 1):S25–38.
60. Bonnie RJ, Stratton K, Kwan LY. Institute of Medicine, public health implications of raising the minimum age of legal access to Tobacco products. Washington (DC): National Academy of Sciences; 2015.
61. Holford TR, Levy DT, Meza R. Comparison of Smoking history patterns among African American and white cohorts in the United States born 1890 to 1990. *Nicotine Tob Res*. 2016;18(Suppl 1):S16–29.
62. Dai H, Leventhal AM. Prevalence of e-Cigarette use among adults in the United States, 2014–2018. *JAMA*. 2019;322(18):1824–7.
63. Vardavas CI, Filippidis FT, Agaku IT. Determinants and prevalence of e-cigarette use throughout the European Union: a secondary analysis of 26 566 youth and adults from 27 countries. *Tob Control*. 2015;24(5):442–8.
64. Kotz D, Bockmann M, Kastaun S. The use of Tobacco, E-cigarettes, and methods to quit Smoking in Germany. *Dtsch Arztebl Int*. 2018;115(14):235–42.
65. Schoenborn CA, Gindi RM. Electronic Cigarette use among adults: United States, 2014. *NCHS Data Brief*. 2015;217:1–8.
66. Chapter 2, Patterns of E-Cigarette Use Among U.S. Youth and Young Adults., in *E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General*, National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health., Editor. 2016, Centers for Disease Control and Prevention (US: Atlanta, GA).
67. Levy DT, et al. Examining the relationship of vaping to smoking initiation among US youth and young adults: a reality check. *Tob Control*. 2018;28(6):629–35.
68. Levy DT, Yuan Z, Li Y. The prevalence and characteristics of E-Cigarette users in the U.S. *Int J Environ Res Public Health*. 2017;14(10)
69. National Center for Health Statistics. Percentage of Adults Aged 18–24 Years Who Currently Smoke Cigarettes or Who Currently Use Electronic Cigarettes, by Year — National Health Interview Survey, United States, 2014–2018. 2019 [cited 2018 December 8]; Available from: <https://www.cdc.gov/mmwr/volumes/68/wr/mm6839a6.htm>.
70. Lampert T, Kuntz B, Ki GGSSG. Tobacco and alcohol consumption among 11- to 17-year-old adolescents: results of the KiGGS study: first follow-up (KiGGS wave 1). *Bundesgesundheitsbl Gesundheitsforsch Gesundheitschutz*. 2014;57(7):830–9.
71. Schaller K, et al. In: *Krebsforschungszentrum D, editor. Tabakatlas Deutschland 2020*. Lengerich, Germany: Pabst Science Publishers; 2020.
72. Cantrell J, et al. Patterns in first and daily cigarette initiation among youth and young adults from 2002 to 2015. *PLoS One*. 2018;13(8):e0200827.
73. Bullen C, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet*. 2013;382(9905):1629–37.
74. Levy DT, et al. The relationship of E-Cigarette use to Cigarette quit attempts and cessation: insights from a large, nationally representative U.S. Survey *Nicotine Tob Res*. 2018;20(8):931–9.
75. Hajek P, et al. A randomized trial of E-cigarettes versus nicotine-replacement therapy. *N Engl J Med*. 2019;380(7):629–37.
76. Zhu SH, et al. E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys. *BMJ*. 2017;358:j3262.
77. Levy DT, et al. Comparison of smoking prevalence in Canada before and after nicotine vaping product access using the SimSmoke model. *Can J Public Health*. 2023;
78. Levy DT, et al. The Australia Smoking and Vaping model: the potential impact of increasing access to nicotine Vaping products. *Nicotine Tob Res*. 2023;25(3):486–97.
79. Nutt DJ, et al. E-cigarettes are less harmful than smoking. *Lancet*. 2016;387(10024):1160–2.
80. McNeill A, et al. Vaping in England: an evidence update including mental health and pregnancy, march 2020: a report commissioned by Public Health England. London: Public Health England; 2020.
81. Eissenberg T, et al. Invalidity of an oft-cited estimate of the relative harms of electronic cigarettes. *Am J Public Health*. 2020;110(2):161–2.
82. Tam J, et al. Projecting the effects of tobacco control policies in the USA through microsimulation: a study protocol. *BMJ Open*. 2018;8(3):e019169.
83. European Commission. Eurobarometer. [cited 2021 July 2021]; Available from: <https://europa.eu/eurobarometer/surveys/browse/all/series/4961>.
84. Health status, behaviour relevant to health. Smoking habits by sex and age-group: Results from Microcensus 2017. 2017 [cited 2021 July 26]; Available from: <https://www.destatis.de/EN/Themes/Society-Environment/Health/Health-Status-Behaviour-Relevant-Health/Tables/liste-smoking-habits-sex-age-groups.html>.
85. Kotz, D. DEBRA Study. Deutsche Befragung zum Rauchverhalten. 2021 [cited 2021 Spetember 2021]; Available from: <https://www.debra-study.info/>.
86. Lampert T, et al. Gesundheitsberichterstattung des Bundes: Ziele, Aufgaben und Nutzungsmöglichkeiten. Hrsg. Robert Koch-Institut Berlin. GBE kompakt; 2010. p. 1.
87. Levy DT, et al. An examination of the variation in estimates of E-Cigarette prevalence among U.S. Adults *Int J Environ Res Public Health*. 2019;16(17)

88. Gallus S, et al. Use and awareness of heated Tobacco products in Europe. *J Epidemiol*. 2021;
89. Maria Lotrean L, et al. Awareness and use of heated tobacco products among adult smokers in six European countries: findings from the EUREST-PLUS ITC Europe surveys. *Eur J Pub Health*. 2020;30(Suppl\_3):iii78–83.
90. Jeon J, et al. Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation. *Risk Anal*. 2012;32(1):S51–68.
91. Tam J, et al. Patterns of Birth Cohort–Specific Smoking Histories in Brazil. *Am J Prev Med*. 2023;64(4 Suppl 1):S63–71.
92. Kenfield SA, et al. Smoking and smoking cessation in relation to mortality in women. *JAMA*. 2008;299(17):2037–47.
93. Zhu D, Zhao G, Wang X. Association of Smoking and Smoking Cessation with Overall and cause-specific mortality. *Am J Prev Med*. 2021;60(4):504–12.
94. Teshima A, Lavery AA, Filippidis FT. Burden of current and past smoking across 28 European countries in 2017: a cross-sectional analysis. *Tob Induc Dis*. 2022;20:56.
95. Meza R, Jimenez-Mendoza E, Levy DT. Trends in Tobacco use among adolescents by grade, sex, and race, 1991–2019. *JAMA Netw Open*. 2020;3(12):e2027465.
96. McNeill A, Brose LS, Calder R, Bauld L, Robson D. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England. London: Public Health England; 2018.
97. Fairchild AL, Bayer R, Lee JS. The E-Cigarette debate: what counts as evidence? *Am J Public Health*. 2019;109(7):1000–6.
98. Green SH, Bayer R, Fairchild AL. Evidence, policy, and E-cigarettes. *N Engl J Med*. 2016;375(5):e6.
99. Abrams DB. Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete? *JAMA*. 2014;311(2):135–6.
100. Levy D, et al. An economic analysis of the pre-deeming US market for nicotine Vaping products. *Tob Regul Sci*. 2019;5(2):169–81.
101. Coleman B, et al. Transitions in electronic cigarette use among adults in the population assessment of Tobacco and health (PATH) study, waves 1 and 2 (2013–2015). *Tob Control*. 2018;
102. Azagba S, Shan L, Latham K. Adolescent dual use classification and its association with nicotine dependence and quit intentions. *J Adolesc Health*. 2019;65(2):195–201.
103. Borland R, et al. A new classification system for describing concurrent use of nicotine vaping products alongside cigarettes (so-called ‘dual use’): findings from the ITC-4 country Smoking and Vaping wave 1 survey. *Addiction*. 2019;
104. Robertson L, et al. Dual use of electronic nicotine delivery systems (ENDS) and smoked tobacco: a qualitative analysis. *Tob Control*. 2019;28(1):13–9.
105. Czoli CD, et al. Awareness and interest in IQOS heated tobacco products among youth in Canada. England and the USA *Tob Control*. 2020;29(1):89–95.
106. Glantz SA. Heated tobacco products: the example of IQOS. *Tob Control*. 2018;27(Suppl 1):s1–6.
107. Hwang JH, Ryu DH, Park SW. Heated tobacco products: Cigarette complements, not substitutes. *Drug Alcohol Depend*. 2019;204:107576.
108. Graen L, Schaller K. Strategy for a tobacco-free Germany 2040, d.G.C.R. Center, editor. Heidelberg, Germany: DKFZ; 2021.
109. Tobacco Control in Europe. Excerpt from the Tobacco atlas Germany 2020. Heidelberg, Germany: G.C.R. Center, Editor; 2020.
110. Parties to the WHO FCTC (ratifications and accessions). 2017; Available from: <https://fctc.org/parties-ratifications-and-accessions-latest/>.
111. World Health Organization. WHO report on the global tobacco epidemic 2021: addressing new and emerging products. Geneva: WHO; 2021.
112. World Health Organization. The Global Health Observatory. [cited 2021 February 2021]; Available from: [https://www.who.int/data/gho/data/indicators/indicator-details/GHO/adult-mortality-rate-\(probability-of-dying-between-15-and-60-years-per-1000-population\)](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/adult-mortality-rate-(probability-of-dying-between-15-and-60-years-per-1000-population)).
113. Global Health Observatory. Life expectancy and healthy life expectancy. [cited 2021 February 2021]; Available from: <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy>.
114. Gopal Health Observatory data repository. [cited 2021 February ]; Available from: <http://apps.who.int/gho/data/node.main.65>.
115. Holford TR, et al. Patterns of birth cohort-specific smoking histories, 1965–2009. *Am J Prev Med*. 2014;46(2):e31–7.
116. Jeon J, et al. Smoking and lung Cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. *Ann Intern Med*. 2018;169(10):684–93.
117. CISNET. Smoking histories. 2016 [cited 2019 December 20]; Available from: <https://resources.cisnet.cancer.gov/projects/>.
118. Cullen KA, et al. E-Cigarette use among youth in the United States, 2019. *JAMA*. 2019;322(21):2095–103.
119. Hammond D, et al. Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. *BMJ*. 2019;365:12219.
120. Miech R, et al. Trends in Adolescent Vaping, 2017–2019. *N Engl J Med*. 2019;381(15):1490–1.
121. Miech R, et al. Adolescent Vaping and nicotine use in 2017–2018 - U.S. National Estimates. *N Engl J Med*. 2019;380(2):192–3.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

